About NaviGate CSI
Given the unmet clinical need for patients with moderate or greater functional valve regurgitation (FTR)/ tricuspid insufficiency, NCSI is developing a catheter-guided atrioventricular valved stent for replacement of a failing tricuspid valve. Innovative anchoring mechanisms serve to secure and maintain positioning of the replacement valve.
The Technology
The GATE™ System is designed to provide a novel, bio-prosthetic solution for treatment of moderate or greater functional tricuspid regurgitation.
Navigate FAQ's
Tricuspid regurgitation (insufficiency) is a clinical condition that affects millions of people worldwide. While citations in the literature estimated that more than 1.6 million Americans had moderate to severe tricuspid regurgitation in 2006, data presented by key opinion leaders in 2018 estimate that as many as 2.5 million Americans may now be affected.
NCSI is developing a solution for heart teams to treat tricuspid regurgitation/insufficiency through valve replacement.
Early clinical studies in humans are anticipated to begin in Summer 2019.
Our Mission
The mission of NaviGate Cardiac Structures, Inc., is to be the leader in development of innovative transcatheter bioprosthetic heart valve implants for treating the unmet needs of atrioventricular valve disease.
In the News
iVascular SLU, Barcelona Invests in NaviGate Cardiac Structures, Inc.
At the end of 2018, iVascular SLU, a European medical device company, made an investment in NaviGate Cardiac Structures, Inc. and will be instrumental in helping the company’s developments by providing its expertise in fabrication and manufacturing of various...
Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada.
Communiqué de presse PREMIÈRE MÉDICALE CANADIENNE : UN 10E CAS DE REMPLACEMENT TRICUSPIDE PERCUTANÉ AU MONDE RÉALISÉ À L’INSTITUT Québec, 8 février 2018 – L’Institut universitaire de cardiologie et de pneumologie de Québec– Université Laval (l’Institut) a récemment...
NaviGate Cardiac Structures, Inc., presents data of studies on the Gate™ valved stent for correction of Functional Tricuspid Regurgitation at Paris PCR2016.
Jose L Navia, M.D., from Cleveland Clinic presented the summary of animal studies of the Gate™valved stent for catheter-guided orthotopic implantation procedure for the correction of Functional Tricuspid Regurgitation (FTR). Functional tricuspid regurgitation occurs...